Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 40, 2011, Pages 16753-16758

  Du, Yi Chieh Nancy ^a,b   Chou, Chen Kung ^c   Klimstra, David S ^a   Varmus, Harold ^a,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECEPTOR; RECEPTOR FOR HYALURONAN MEDIATED MOTILITY ISOFORM B; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; GENE TRANSFER; LIVER METASTASIS; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ADENOMA, ISLET CELL; ANIMALS; ANTIGENS, CD44; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; GENE TRANSFER TECHNIQUES; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER NEOPLASMS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

MUS;

EID: 80053631995     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1114022108     Document Type: Article

References (25)

1. Du YC, Lewis BC, Hanahan D, Varmus H (2007) Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biol 5:e276.
2. Yang CW, et al. (2005) Integrative genomics based identification of potential human hepatocarcinogenesis-associated cell cycle regulators: RHAMM as an example. Biochem Biophys Res Commun 330:489-497.
3. Akiyama Y, et al. (2001) Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol 53:115-127. (Pubitemid 33034687)
4. Assmann V, et al. (2001) The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J Pathol 195:191-196. (Pubitemid 32899028)
5. Grützmann R, et al. (2004) Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 6:611-622. (Pubitemid 39411099)
6. Gust KM, et al. (2009) RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 11:956-963.
7. Zlobec I, Baker K, Terracciano LM, Lugli A (2008) RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res 14:3798-3806.
8. Ota T, et al. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet 36:40-45. (Pubitemid 38056206)
9. Sohr S, Engeland K (2008) RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle 7:3448-3460.
10. Tolg C, et al. (2006) Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J Cell Biol 175:1017-1028. (Pubitemid 44969206)
11. Monslow J, Sato N, Mack JA, Maytin EV (2009) Wounding-induced synthesis of hyaluronic acid in organotypic epidermal cultures requires the release of heparin-binding egf and activation of the EGFR. J Invest Dermatol 129:2046-2058.
12. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G (1998) A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392:190-193. (Pubitemid 28162793)
13. Ciardiello F, et al. (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063. (Pubitemid 30305105)
14. Chen C-H, et al. (2007) FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene 26:4272-4283. (Pubitemid 46975797)
15. Chen C-H, et al. (2009) Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene 28:2723-2737.
16. Hofmann M, et al. (1998) Problems with RHAMM: A new link between surface adhesion and oncogenesis? Cell 95:591-592, author reply 592-593.
17. Maxwell CA, McCarthy J, Turley E (2008) Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions? J Cell Sci 121:925-932. (Pubitemid 351639411)
18. Nolan-Stevaux O, et al. (2010) Differential contribution to neuroendocrine tumorigenesis of parallel Egfr signaling in cancer cells and pericytes. Genes Cancer 1:125-141.
19. Li W, Liang X, Kellendonk C, Poli V, Taub R (2002) STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 277:28411-28417. (Pubitemid 41079264)
20. Podsypanina K, et al. (2008) Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321:1841-1844.
21. Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115-122.
22. Maxwell CA, et al. (2004) RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 104:1151-1158. (Pubitemid 39038037)
23. Fekete DM, Cepko CL (1993) Replication-competent retroviral vectors encoding alkaline phosphatase reveal spatial restriction of viral gene expression/transduction in the chick embryo. Mol Cell Biol 13:2604-2613. (Pubitemid 23097739)
24. Kang Y, et al. (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102:13909-13914. (Pubitemid 41377677)
25. Du YC, Klimstra DS, Varmus H (2009) Activation of PyMT in beta cells induces irreversible hyperplasia, but oncogene-dependent acinar cell carcinomas when activated in pancreatic progenitors. PLoS ONE 4:e6932.